Global Market Report

Global Biomarkers Market Forecast to 2029

The global biomarkers market is expected to grow at a CAGR of 9.9% in the first half of the forecast period. In 2018, the largest sector of the market was biomarker discovery, which encompasses revenues for instruments and reagents, as well as the other costs associated with in-house biomarker research and development. This sector accounted for 48% of the global biomarkers market.

SKU: PHA0598 Categories: , , Tags: , , Code: PHA0598Pages: 170
Clear
← Back to category Biotechnology

Description

The global biomarkers market is expected to grow at a CAGR of 9.9% in the first half of the forecast period. In 2018, the largest sector of the market was biomarker discovery, which encompasses revenues for instruments and reagents, as well as the other costs associated with in-house biomarker research and development. This sector accounted for 48% of the global biomarkers market sector.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 170-page report you will receive 104 charts, all unavailable elsewhere.

The 170-page report provides clear detailed insight into the global biomarkers market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Biomarkers Market forecasts to 2029

• This report also breaks down the revenue forecast for the global biomarkers market by Product:
• Consumables
• Services
• Software

• This report also breaks down the revenue forecast for the global biomarkers market by Sector:
• Biomarker Services
• Biomarker Diagnostics
• Biomarker Discovery

• This report also breaks down the revenue forecast for the global biomarkers market by Type:
• Safety Biomarkers
• Efficacy Biomarkers
• Validation Biomarkers

• This report also breaks down the revenue forecast for the global biomarkers market by Discipline:
• Genomics
• Proteomics
• Bioinformatics
• Other

• This report also breaks down the revenue forecast for the global biomarkers market by Therapeutic Indication:
• Cancer
• Cardiovascular Diseases
• CNS
• Autoimmune Diseases
• Other

Global Biomarkers Market Forecast to 2029

• This report provides individual revenue forecasts to 2029 for these regional and national markets:
• North America: US, Canada
• Europe: Germany, UK, France, Spain, Italy, Rest of Europe
• Asia-Pacific: China, Japan, India, Australia, South Korea, Rest of APAC
• Middle East & Africa: South Africa, Saudi Arabia, Rest of Middle East & Africa
• Latin America: Brazil, Mexico, Rest of Latin America

• Our study gives qualitative analysis of the biomarkers market. It includes a SWOT and STEP Analysis.

• Our study discusses the selected leading companies that are the major players in the biomarkers industry. These companies are biomarker service providers, biomarker technology providers and biomarker diagnostic developers:
• AB SCIEX
• Agilent
• Axela Inc
• Caprion Proteomics
• Charles River Laboratories
• Critical Diagnostics
• Epigenomics
• Genomic Health
• ICON plc
• Laboratory Corporation of America Holdings
• MDxHealth (formerly OncoMethylome)
• Myriad Genetics
• Oxford Gene Technology (OGT)
• Pacific Biomarkers
• Parexel
• Proteome Sciences
• QIAGEN
• Quest Diagnostics
• Quintiles IMS Holdings Inc
• Thermo Fisher Scientific
• Worldwide Clinical Trials (WWC)
• WuXi PharmaTec

• Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs:
• Pfizer
• Novartis
• Roche Diagnostics
• Ventana Medical Systems
• Merck & Co.
• Sanofi
• GSK
• Abbott Laboratories
• AstraZeneca

• Key questions answered by this report:
• How is the biomarkers market evolving?
• What is driving and restraining the biomarker market dynamics?
• Which trends and developments will prevail?
• How will the market shares of the regional markets change by 2029 and which geographical region will lead the market in 2029?
• Who are the leading players and what are their prospects over the forecast period?

Visiongain’s study is intended for anyone requiring commercial analyses for the global biomarkers market. You find data, trends and predictions.

Buy our report today Global Biomarkers Market Forecast: Consumables, Services, Software, Biomarker Discovery, Biomarker Diagnostics, Biomarker Services, Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS Diseases, Autoimmune Diseases.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

1. Report Overview
1.1 Biomarkers: World Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report Include
1.5 Who is this report for?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. An Introduction to Biomarkers
2.1 Definition of a Biomarker
2.1.1 A Brief History of Biomarkers
2.1.2 The Importance of Biomarkers
2.2 Biomarker Discovery and Validation
2.3 Uses of Biomarkers
2.3.1 Assessing Drug Efficacy
2.3.2 Assessing Drug Safety
2.3.3 Companion Diagnostics
2.3.4 Therapeutic Importance of Biomarkers
2.3.5 Imaging Biomarkers
2.4 Biomarkers and Personalised Medicine
2.5 Biomarker Discovery
2.5.1 Genomics
2.5.2 Proteomics
2.5.3 Metabolomics

3.The World Biomarkers Market Forecast to 2029
3.1 The World Biomarkers Market, 2018
3.1.1 The World Biomarkers Market: Overall Revenue Forecast to 2029
3.1.2 Lack of Investment and Reimbursement Issues May Restrain Market
3.2 The World Biomarkers Market by Product, 2018
3.2.1 The World Biomarkers Market by Product, 2018-2029
3.3 The World Biomarkers Market by Sector, 2018
3.3.1 The World Biomarkers Market by Sector, 2018-2029
3.4 The World Biomarkers Market by Type, 2018
3.4.1 The World Biomarkers Market by Type, 2018-2029
3.5 The World Biomarkers Market by Discipline, 2018
3.5.1 The World Biomarkers Market by Discipline, 2018-2029

4. Leading Disease Indications for Biomarker Discovery and Development: Forecast to 2029
4.1 The World Biomarkers Market by Disease Indication, 2018
4.2 The World Biomarkers Market: Overall Revenue Forecast by Indication, 2018-2029
4.3 Cancer Biomarker Market
4.3.1 A Brief History of Cancer Biomarker Research
4.3.2 The Current State of Cancer Biomarker Research
4.3.3 Companion Diagnostics for Cancer
4.3.4 Initiatives in Cancer Biomarker Research
4.3.4.1 Cancer Genome Atlas
4.3.4.2 The Early Detection Research Network
4.3.5 Many Cancer Diagnostics Are Reaching the Market
4.3.6 Opportunities and Challenges for Cancer Biomarkers
4.3.7 Cancer Biomarker Submarket: Revenue Forecast, 2018-2029
4.4 Cardiovascular Disease Biomarker Submarket 2018
4.4.1 A Brief History of Cardiovascular Biomarker Research
4.4.2 The Current State of Cardiovascular Disease Biomarker Research
4.4.3 Cardiovascular Disease Diagnostics
4.4.4 Collaborations in Cardiac Biomarker Research
4.4.5 The Future of Cardiovascular Biomarker Research
4.4.6 Cardiovascular Disease Biomarker Submarket: Revenue Forecast, 2018-2029
4.5 CNS Diseases Biomarker Submarket, 2018
4.5.1 The Current State of CNS Disease Biomarker Research
4.5.2 Initiatives in CNS Disease Biomarker Research
4.5.3 Biomarker-Based Diagnostics for CNS Diseases
4.5.3 Biomarker-Based Diagnostics for CNS Diseases
4.5.3.1 ADtect (DiaGenic)
4.5.3.2 Pittsburgh Compound B (PIB) (GE Healthcare)
4.5.3.3 Florbetapir F18 (18F-AV-45) (Eli Lilly)
4.5.3.4 Flutemetamol (GE Healthcare)
4.5.3.5 Florbetaben (Piramal Imaging)
4.5.4 CSF Biomarkers
4.5.5 Alzheimer's Disease: Beyond Amyloid Beta
4.5.5.1 New Criteria and Guidelines to Diagnose Alzheimer's Disease
4.5.6 Multiple Sclerosis: Search for Disease Biomarker
4.5.7 Parkinson's Disease: Effective Biomarker Yet to be Discovered
4.5.7.1 Fluid-Based Biomarker Discovery
4.5.8 CNS Diseases Biomarker Submarket: Revenue Forecast, 2018-2029
4.6 Autoimmune Disease Biomarker Submarket, 2018
4.6.1 Research Initiatives in Biomarker Research for Autoimmune Disease
4.6.2 Marketed Biomarker Diagnostic Tests for Autoimmune Disease
4.6.2.1 Ventra DA - Myriad Genetics
4.6.2.2 NavigAID SSc - Protagen AG
4.6.2.3 Autoimmune Thyroid Disease Tests - Thermo Fischer
4.6.3 Increasing consolidation within the market
4.6.3.1 Merck, Pfizer and Broad Institute Collaborate on biomarkers For Autoimmune Disorders
4.6.3.2 Protagen AG and Qiagen on Protein Based Companion Diagnostics
4.6.4 Autoimmune Diseases Biomarker Submarket: Revenue Forecast, 2018-2029
4.7 Growth in Key Biomarker Indications, 2018-2029

5. Leading National Biomarker Markets Forecast to 2029
5.1 The World Biomarkers Market: Regional Breakdown, 2018
5.2 The World Biomarkers Market: Regional Forecast, 2018-2029
5.3 North America Biomarkers Market, 2018-2029
5.4 Europe Biomarker Markets, 2018-2029
5.5 Asia-Pacific Biomarker Market, 2018-2029
5.6 Latin America Biomarker Market, 2018-2029
5.7 Middle East & Africa Biomarker Market, 2018-2029

6. Biomarker Industry Trends
6.1 Strengths and Weaknesses of the Biomarkers Market, 2018
6.2 Opportunities and Threats in the Biomarkers Market, 2018-2029
6.3 STEP Analysis of The World Biomarkers Market
6.4 Social Factors
6.4.1 Patient Stratification: Striving Towards Personalised Medicine
6.4.2 Biomarker Hype May Not Always Lead to New Discoveries
6.4.3 Growing Emphasis on Oncology for Companies
6.5 Technological Factors
6.5.1 Decreasing Size, Increasing Sensitivity
6.5.1.1 ABT Molecular Imaging
6.5.2 The Need for More-Efficient Data Storage
6.6 Economic Factors
6.6.1 Biomarkers: Cutting the Cost of Drug Development
6.6.1.1 Toxicity Biomarkers: Aiming to Reduce Clinical Drug Failures
6.6.2 High Cost of Technology: Potential Barrier to Entry for Start-Ups
6.6.3 Outsourcing Biomarker Discovery and Development
6.7 Political Factors
6.7.1 Public-Private Partnerships: Collaborative Efforts Aid Biomarker Discovery
6.7.2 Improving Regulatory Guidelines to Speed Development
6.7.3 Concerns Over Biomarker Patenting Hits Innovation
6.8 Challenges in Developing Biomarkers
6.9 Combining Drug and Diagnostic Development
6.10 MicroRNA Biomarkers: A Prospective Target?
6.11 Big Pharma and Biomarkers
6.11.1 Pfizer
6.11.2 Novartis
6.11.3 Merck & Co.
6.11.4 Sanofi
6.11.5 Roche
6.11.5.1 Roche Diagnostics
6.11.5.2 Ventana Medical Systems
6.11.6 GSK
6.11.7 AstraZeneca
6.11.8 Abbott Laboratories

7. Leading Companies in the Biomarkers Market
7.1 Biomarker Service Providers
7.1.1 Global CROs and Biomarkers
7.1.1.1 Not All Global CROs Are Investing in Biomarkers
7.1.2 Quintiles IMS Holdings Inc.
7.1.2.1 Quintiles and IMS Health Merger
7.1.3 Laboratory Corporation of America Holdings
7.1.3.1 LabCorp Diagnostics
7.1.3.2 Covance Drug development
7.1.3.3 Companion and Complimentary Diagnostics Launched for Cancer in 2017
7.1.4 PAREXEL International Corp.
7.1.5 Charles River Laboratories
7.1.6 ICON plc
7.1.7 WuXi PharmaTec
7.1.8 Caprion Proteomics
7.1.9 Proteome Sciences
7.1.10 Pacific Biomarkers
7.1.11 Oxford Gene Technology
7.1.12 Worldwide Clinical Trials
7.2 Biomarker Technology Providers
7.2.1 Agilent
7.2.1.1 Diagnostics and Biomarker Assays
7.2.1.2 Growing Asian Markets: Focus on South Korea
7.2.2 AB SCIEX
7.2.2.1 Partnership with Illumina, OneOmics project
7.2.3 QIAGEN
7.2.4 ANGLE Biosciences, Inc. (Axela)
7.2.5 Thermo Fisher Scientific
7.2.5.1 Strategic Acquisitions
7.2.5.2 Research Collaborations
7.2.5.3 Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Centre
7.3 Biomarker Diagnostic Developers
7.3.1 Quest Diagnostics
7.3.1.1 Acquisitions to expand the product portfolio and geographic presence
7.3.1.2 Q2 Solutions, Join Venture Between Quest Diagnostics and Quintiles IMS Holdings Inc.
7.3.2 Myriad Genetics
7.3.2.1 Pipeline
7.3.2.2 BRACAnalysis Gains Approval as Companion Diagnostic
7.3.2.3 Strategic Acquisitions
7.3.2.4 Myriad RBM
7.3.3 Genomic Health
7.3.3.1 Collaborations with Epic Sciences and Biocartis
7.3.4 Critical Diagnostics
7.3.5 Epigenomics
7.3.5.1 Diagnostic Product Portfolio
7.3.6 MDxHealth
7.3.6.1 Diagnostic Product Portfolio and Pipeline

8. Conclusions
8.1 State of the World Biomarkers Market in 2018
8.2 Growth in the World Biomarkers Market, 2018-2029
8.2.1 Dominance of Leading Western Markets
8.3 The Use of Biomarkers in Drug Discovery and Development
8.4 Demand for New Diagnostics

Appendices
Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 2.1 Selected Drugs with Pharmacogenomic Biomarkers Listed on their Labels, 2018
Table 2.2 Selected Clinically-Relevant Cancer Biomarkers, 2016
Table 2.3 Technologies and Platforms for Biomarker Research, 2018
Table 3.1 World Biomarkers Market: Revenue ($bn) and Market Shares (%) by Product, 2018
Table 3.2 World Biomarkers Market: Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Product, 2018-2029
Table 3.3 World Biomarkers Market: Market Shares (%) by Product, 2018, 2023, 2029
Table 3.4 World Biomarkers Market: Revenue ($bn) and Market Shares (%) by Sector, 2018
Table 3.5 World Biomarkers Market: Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Sector, 2018-2029
Table 3.6 World Biomarkers Market: Market Shares (%) by Sector, 2018, 2023, 2029
Table 3.7 World Biomarkers Market: Revenue ($bn) and Market Shares (%) by Type, 2018
Table 3.8 World Biomarkers Market: Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Type, 2018-2029
Table 3.9 World Biomarkers Market: Market Shares (%) by Type, 2018, 2023, 2029
Table 3.10 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Discipline, 2018
Table 3.11 World Biomarkers Market: Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Discipline, 2018-2029
Table 3.12 World Biomarkers Market: Market Shares (%) by Discipline, 2018, 2023, 2029
Table 4.1 World Biomarkers Market: Market Share (%) by Disease Indication, 2018
Table 4.2 World Biomarkers Market: Overall Market and Revenue Forecasts ($bn, AGR %, CAGR %) by Disease Indication, 2018-2029
Table 4.3 Selected Marketed Biomarker-Based Cancer Diagnostics, 2018
Table 4.4 Cancer Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029
Table 4.5 Cardiovascular Disease Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029
Table 4.6 CNS Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029
Table 4.7 Autoimmune Diseases Submarket: Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029
Table 4.8 World Biomarkers Market: Market Share (%) by Disease Indication, 2018, 2023 and 2029
Table 5.1 World Biomarkers Market: Revenues ($bn) and Market Shares (%) by Country, 2018
Table 5.2 World Biomarkers Market: Revenue Forecasts ($bn, AGR %, CAGR %) by Region, 2018-2029
Table 5.3 World Biomarkers Market: Market Shares (%) by Country, 2018, 2023, 2029
Table 5.4 North America Biomarkers Market: Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029
Table 5.5 Europe Biomarker Markets: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2018
Table 5.6 Europe Biomarkers Markets: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2018-2029
Table 5.7 Asia-Pacific Biomarkers Markets: Revenue Forecasts ($bn, AGR %, CAGR %) by Country, 2018-2029
Table 5.8 Latin America Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029
Table 5.9 Middle East & Africa Biomarker Market Revenue Forecast ($bn, AGR %, CAGR %), 2018-2029
Table 6.1 World Biomarkers Market: Strengths and Weaknesses, 2018-2029
Table 6.2 World Biomarkers Market: Opportunities and Threats, 2018-2029
Table 6.3 World Biomarkers Market: STEP Analysis, 2018-2029
Table 6.4 US Cancer Deaths by Tumour Type, 2018
Table 6.5 Selected Cancer Therapies Approved with a Biomarker, 2018
Table 6.6 PSTC Biomarkers in Development, 2018
Table 6.7 Average Cost of Sequencing the Human Genome: Revenue Forecast ($m, AGR %, CAGR %), 2005-2015
Table 6.8 IMI-Funded Biomarker Projects
Table 7.1 Laboratory Corporation of America: Revenue by Sector ($bn) 2016-2017
Table 7.2 Proteome Sciences: Revenue ($mn), 2016-2017
Table 7.3 Myriad Genetics: Biomarker Product Portfolio, 2017
Table 7.4 Company Revenue by Sector ($mn), 2017
Table 7.5 Myriad Genetics: Diagnostic Pipeline, 2017
Table 7.6 Genomic Health: Revenue by Division ($mn), 2016-2017
Table 7.7 Epigenomics: Revenue and Market Shares by Sector ($mn), 2016-2017
Table 7.8 MDx Health: Revenue by Source ($mn), 2016-2017
Table 7.9 MDxHealth: Pipeline, 2017
Table 8.1 World Biomarkers Market: Revenues ($bn, CAGR %, Market Share %) by Sector, 2018, 2023 and 2029
Table 8.2 World Biomarkers Market: Revenues ($bn, CAGR %, Market Share %) by Discipline, 2018-2023 and 2029
Table 8.3 World Biomarkers Market: Revenues ($bn, CAGR %) by Disease Indication, 2018, 20123 and 2029
Table 8.4 World Biomarkers Market: Revenues ($bn, CAGR %) by Product, 2018, 2023 and 2029
Table 8.5 World Biomarkers Market: Revenues ($bn, CAGR %) by Type, 2018, 2023 and 2029
Table 8.6 World Biomarkers Market: Revenues ($bn, CAGR %) by Region, 2018, 2023 and 2029

List of Figures
Figure 2.1 Definitions of a Biomarker, 2018
Figure 2.2 The Biomarker Discovery and Validation Process, 2018
Figure 3.1 World Biomarkers Market: Drivers and Restraints, 2018-2029
Figure 3.2 World Biomarkers Market: Market Shares (%) by Product, 2018
Figure 3.3 World Biomarkers Market by Product: Market Forecast ($bn), 2018-2029
Figure 3.4 World Biomarkers Market: Market Shares (%) by Product, 2023
Figure 3.5 World Biomarkers Market: Market Shares (%) by Product, 2029
Figure 3.6 World Biomarkers Market: Market Shares (%) by Sector, 2018
Figure 3.7 World Biomarkers Market by Sector: Market Forecast ($bn), 2018-2029
Figure 3.8 World Biomarkers Market: Market Shares (%) by Sector, 2023
Figure 3.9 World Biomarkers Market: Market Shares (%) by Sector, 2029
Figure 3.10 World Biomarkers Market: Market Shares (%) by Type, 2018
Figure 3.11 World Biomarkers Market by Type: Market Forecast ($bn), 2018-2029
Figure 3.12 World Biomarkers Market: Market Shares (%) by Type, 2023
Figure 3.13 World Biomarkers Market: Market Shares (%) by Type, 2029
Figure 3.14 World Biomarkers Market: Market Shares (%) by Discipline, 2018
Figure 3.15 World Biomarkers Market, by Discipline: Market Forecast ($bn), 2018-2029
Figure 3.16 World Biomarkers Market: Market Shares (%) by Discipline, 2023
Figure 3.17 World Biomarkers Market: Market Shares (%) by Discipline, 2029
Figure 4.1 World Biomarkers Market: Market Share (%) by Disease Indication, 2018
Figure 4.2 Cancer Submarket: Revenue Forecast ($bn), 2018-2029
Figure 4.3 Cardiovascular Disease Submarket: Revenue Forecast ($bn), 2018-2029
Figure 4.4 CNS Diseases Submarket: Revenue Forecast ($bn), 2018-2029
Figure 4.5 Autoimmune Diseases Submarket: Revenue Forecast ($bn), 2018-2029
Figure 4.6 World Biomarkers Market: Market Share (%) by Disease Indication, 2023
Figure 4.7 World Biomarkers Market: Market Shares (%) by Disease Indication,2029
Figure 5.1 World Biomarkers Market: Market Shares (%) by Country, 2018
Figure 5.2 World Biomarkers Market: Market Shares (%) by Country, 2023
Figure 5.3 World Biomarkers Market: Market Shares (%) by Country, 2029
Figure 5.4 North America Biomarkers Market: Revenue Forecast ($bn), 2018-2029
Figure 5.5 Europe Biomarker Markets: Market Share (%) by Country, 2018
Figure 5.6 Europe Biomarker Markets: Revenue Forecasts ($bn), 2018-2029
Figure 5.7 Asia-Pacific Biomarker Market: Revenue Forecasts ($bn), 2018-2029
Figure 5.8 Latin America Biomarker Market Revenue Forecast ($bn), 2018-2029
Figure 5.9 Middle East & Africa Biomarker Market Revenue Forecast ($bn), 2018-2029
Figure 6.1 US Cancer Deaths by Tumour Type, 2018
Figure 6.2 Average Cost of Sequencing the Human Genome ($m), 2005-2015
Figure 7.1 Laboratory Corporation of America: Revenue by Sector ($bn), 2016-2017
Figure 7.2 Proteome Sciences: Revenue ($mn), 2016-2017
Figure 7.3 Myriad Genetics: Market Shares by Molecular Diagnostic Product (%), 2017
Figure 7.4 Genomic Health: Product Revenue ($mn), 2016-2017
Figure 7.5 Epigenomics Revenue ($mn), 2016-2017
Figure 7.6 MDx Health: Revenue by Source ($mn), 2016-2017
Figure 8.1 World Biomarkers Market: Revenues ($bn) by Sector, 2018, 2023 and 2029
Figure 8.2 World Biomarkers Market: Revenues ($bn) by Discipline, 2016, 2021 and 2027
Figure 8.3 World Biomarkers Market: Revenues ($bn) by Disease Indication, 2018, 2023 and 2029
Figure 8.4 World Biomarkers Market: Revenues ($bn) by Product, 2018, 2023 and 2029
Figure 8.5 World Biomarkers Market: Revenues ($bn) by Type, 2018, 2023 and 2029
Figure 8.6 World Biomarkers Market: Revenues ($bn) by Country, 2018, 2023 and 2029

454 Life Sciences
AB SCIEX
Abbott Laboratories
Abbott Molecular
Abcodia
ABT Molecular Imaging
ACS Biomarker
Advanced Cell Diagnostics (ACD)
Advion Bioanalytical Labs (part of Quintiles)
Affymetrix
Agendia
Agilent
Alacris Theranostics
Alere
Amarantus BioSciences
Amgen
Applied Biosystems (part of Life Technologies)
Aptiv Solutions
Arctic Partners
ARIAD Pharmaceuticals
Ariana Pharma
Arizona State University
Arrayit
ARUP Laboratories
AstraZeneca
Athena Diagnostics (a subsidiary of Quest Diagnostics)
Atherotech Diagnostics Lab
Aushon Biosystems
Axela Inc
Bayer
Belfer Institute for Applied Cancer Science [US]
Berkeley HeartLab (a subsidiary of Quest Diagnostics)
BG Medicine
BGI (formerly Beijing Genomics Institute)
Biofortis
Biosoft
BRAHMS (part of Thermo Fisher Scientific)
Brigham and Women's Hospital
Bristol-Myers Squibb
Cancer Research Technology
Caprion Proteomics
CBC (Comprehensive Biomarker Centre GmbH)
Celera (part of Quest Diagnostics)
Celgene
Cell Signaling Technology
Celldex Therapeutics
Cephalon (part of Teva)
Charles River Laboratories
Chronix Biomedical
Chugai Pharmaceutical
Ciphergen Biosystems
Clarient Diagnostic Services
Cleveland HeartLab
Clinigene International
Comprehensive Biomarker Center (formerly Febit)
Covance
Crelux
Critical Diagnostics
Critical Path Institute (C-Path) [US]
CTI Biotech
Daiichi Sankyo
Dako (now part of Agilent)
Dana-Farber Cancer Institute [US]
Danaher
DaVita Labs
DiaGenic
Durin Technologies
DxS (now part of QIAGEN)
EKO Diagnostic
Eli Lilly and Co.
Epic Sciences
Epigenomics
Epistem
EQT
Evotec
Exact Sciences
Exiqon
Exonhit
Ezose Sciences (part of Shionogi)
FEI Company
Foundation Medicine
Fujirebio Diagnostics
GE Healthcare
Genetic Technologies
Geneva Bioinformatics (GeneBio)
Genomic Health
GenWay Biotech
Great Point Partners
GSK
HD Biosciences
Health Diagnostic Laboratory
HealthLinx
Helicos BioSciences
Hewlett-Packard
HTG Molecular Diagnostics
ICON Plc
Illumina
ImmunId
Insight Genetics
Institute of Pathology Heidelberg (IPH)
Integrated Diagnostics
Ipsen
Ipsogen (a subsidiary of QIAGEN)
Isogen Life Science
Johnson & Johnson (J&J)
KU Leuven (University of Leuven)
LabCorp
Life Technologies
LightArray Biotech
M2Gen
Mayo Clinic [US]
Mayo Collaborative Services
MDxHealth
Medical Research Council [UK]
MediMedia Pharma Solutions
Memorial Sloan-Kettering Cancer Center [US]
Merck & Co.
Merck KGaA
Metabolon
Michael J Fox Foundation
Myriad Genetics
Myriad RBM (formerly Rules-Based Medicine, part of Myriad Genetics)
National Academy of Sciences (NAS) [US]
Nephromics
Novartis
Novartis Molecular Diagnostics (part of Novartis)
NovioGendix
Oncoimmune
Oncomedics
OpGen
OPKO Health
Orion Genomics
Oxford Cancer Biomarkers
Oxford Gene Technology
Pacific Biomarkers
Pacific Biosciences
Panomics (now part of Affymetrix)
Parexel
Patheon
Pathwork Diagnostics
Personal Genome Diagnostics
Pfizer
Pierre Fabre
PLUS Diagnostics
PMDA
Power3 Medical Products
PPD
Predictive Biosciences
Prometheus Laboratories
ProtagenAG
Proteome Sciences
QIAGEN
QLIDA Diagnostics
Quanterix
Quanticel Pharmaceuticals
Quest Diagnostics
Quintiles
Quintiles IMS Holdings Inc
Randox Laboratories
Randox Laboratories
Roche
SABiosciences (now part of QIAGEN)
Sandor Proteomic
Sanger Institute
Sanofi
Santaris Pharma
Servier
Shionogi
Siemens
Siemens Healthcare
Singulex Inc
Sividion Diagnostics
SMA Foundation [US]
Stemina Biomarker Discovery
Sysmex
Technology Strategy Board (TSB) [UK]
Teva Pharmaceutical Industries
Thallion Pharmaceuticals
The Biomarkers Consortium
Thermo Fisher Sciences
Thermo Fisher Scientific
Transgene
Trans-Hit Biomarkers
Tufts Center for the Study of Drug Development
Ventana Medical Systems
Vertex Pharmaceuticals
WaferGen
Warnex
Worldwide Clinical Trials
WuXi AppTec
Wuxi Pharmatech
Xcovery

List of Organizations Mentioned in the Report
American College of Cardiology Foundation (ACCF)
American Heart Association (AHA)
Association for Molecular Pathology (AMP) [US]
British Heart Foundation [UK]
Broad Institute [US]
Cancer Research UK
Centers for Medicare and Medicaid Services (CMS) [US]
Chinese State Food and Drug Administration (SFDA)
Commonwealth Scientific and Industrial Research Organisation (CSIRO) [Australia]
EMA (European Medicines Agency)
ETH Zurich
European Commission
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
European Stroke Research Network for Hypothermia (Euro-HYP)
Food and Drug Administration (FDA) [US]
Hirosaki University
Human Proteome Organisation (HUPO)
International Cancer Genome Consortium (ICGC)
Les entreprises du médicament (LEEM) [France]
Malmö University
Massachusetts General Hospital
Max Planck Institute for Molecular Genetics [Germany]
National Academy of Sciences
National Cancer Institute (NCI) [US]
National Health Service (NHS) [UK]
National Human Genome Research Institute (NHGRI) [US]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institute of Allergy and Infectious Diseases (NIAID) [US]
National Institute on Aging (NIA) [US]
National Jewish Health [US]
Newcastle University [UK]
NIH (National Institute of Health)
Oslo University Hospital
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
Predictive Safety Testing Consortium (PSTC) [US]
Shanghai Jiao Tong University
Stanford University
State Food and Drug Administration (SFDA) [China]
Technion-Israel Institute of Technology
University of Alabama
University of Medicine and Dentistry of New Jersey (UMDNJ)
University of Oslo
University of Turku
University of Washington
Wellcome Trust Sanger Institute [UK]
World Health Organization (WHO)